Laurus Labs logo

Laurus Labs

LAURUSLABS NSE

Key Fundamentals

MidcapPharmaceuticalsHealthcare
Market Cap
1.0L Cr
Volatility
Moderate
P/E Ratio
97.28
EBITDA
₹1,833 Cr
Return on Equity
16.38%
Debt to Equity
0.48
Book Value
₹98.09
EPS
₹2.75
52W High
₹1,955
52W Low
₹823.1

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

1
  • Company has been maintaining a healthy dividend payout of 19.0%

Weaknesses

4
  • Stock is trading at 20.1 times its book value
  • The company has delivered a poor sales growth of 7.19% over past five years.
  • Company has a low return on equity of 10.1% over last 3 years.
  • Company might be capitalizing the interest cost

Growth Rate

Revenue Growth
22.01% higher than 3Y
Net Income Growth
151% higher than 3Y
Cash Flow Change
170% higher than 3Y
ROE
113% higher than 3Y
ROCE
62.83% lower than 3Y
EBITDA Margin (Avg.)
32.87% lower than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 2d ago
AI opinion · based on fundamentals
Risk high

Laurus Labs Ltd, with a market cap of ₹1,04,478 Cr, is trading at a PE of 95.9x and 19.74x book value. The company has shown a sharp TTM profit recovery of 115% and 1-year stock CAGR of 117%, but its 5-year compounded profit growth stands at -2% and 5-year sales CAGR is a modest 7%, reflecting an uneven long-term growth trajectory.

Bull Case 8
  • TTM compounded profit growth of 115% signals a strong earnings recovery cycle after a prolonged downturn
  • 1-year stock CAGR of 117% reflects significant re-rating driven by improving business fundamentals
  • TTM sales growth of 23% indicates a meaningful acceleration compared to the 3-year sales CAGR of just 4%
  • Last year ROE of 18% marks a notable improvement from the 3-year average of 10%, suggesting improving capital efficiency
  • 10-year compounded profit growth of 21% demonstrates a credible long-term earnings track record despite recent volatility
  • 10-year compounded sales CAGR of 14% shows the company has scaled meaningfully over the longer term
  • Company has maintained a healthy dividend payout ratio of 19.0%, providing some return to shareholders even during lean years
  • 3-year stock CAGR of 72% indicates sustained investor interest beyond just the recent rally
Bear Case 8
  • PE ratio of 95.9x is extremely elevated, pricing in substantial future growth and leaving little margin for execution missteps
  • Price-to-book of 19.74x is very high, well above typical pharma peers, indicating rich valuation relative to net assets
  • 5-year compounded profit growth of -2% shows earnings actually declined over a medium-term horizon, raising durability concerns about the current recovery
  • 5-year compounded sales growth of only 7% is modest for a company commanding a near-100x PE multiple
  • 3-year ROE of just 10% is low for a healthcare company of this scale and suggests historically weak profitability on equity deployed
  • Dividend yield of 0.1% is negligible, offering virtually no income cushion to investors in a downturn
  • Potential capitalization of interest costs could be flattering reported profitability, masking the true cost structure
  • 3-year compounded sales growth of only 4% highlights that the recent 23% TTM acceleration is not yet proven to be sustainable

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 3h ago
Neutral 1
  • Antique Pharma Investor Day attendance Aug 31

    Laurus Labs confirmed participation in the Antique Pharma Investor Day on September 7, 2026, in Hyderabad. Disclosed via regulatory filing as an in-person meeting.

TL;DR: Limited recent news flow for Laurus Labs with only a routine investor conference attendance announced. No material headwinds or positive catalysts emerged in this period. The lack of negative news is mildly reassuring, but investors should watch for updates from the September 7 Antique Pharma Investor Day for fresh forward guidance.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
1,182
1,224
1,195
1,440
1,195
1,224
1,415
1,720
1,570
1,653
1,778
1,812
2,026
Expenses
1,015
1,037
1,014
1,198
1,024
1,045
1,130
1,300
1,187
1,250
1,298
1,299
1,388
Operating Profit
167
188
181
241
171
178
285
421
382
403
480
512
638
OPM %
14%
15%
15%
17%
14%
15%
20%
24%
24%
24%
27%
28%
32%
Other Income
4
2
2
19
3
5
9
59
10
27
6
12
9
Interest
39
42
51
50
49
53
58
56
52
40
39
40
42
Depreciation
91
93
98
102
106
108
106
110
117
120
121
122
124
PBT
41
54
35
107
18
23
131
312
224
270
327
361
481
Tax %
30%
27%
27%
30%
34%
22%
31%
25%
28%
28%
22%
22%
25%
Net Profit
27
37
23
75
13
20
93
233
162
194
252
282
362
EPS in Rs
0.46
0.69
0.43
1.4
0.23
0.37
1.71
4.33
3.02
3.61
4.66
5.17
6.8
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,327
1,778
1,905
2,056
2,292
2,832
4,814
4,936
6,041
5,041
5,554
6,813
7,270
Expenses
1,126
1,415
1,497
1,642
1,935
2,266
3,262
3,512
4,448
4,261
4,499
5,028
5,236
Operating Profit
200
362
408
414
357
565
1,552
1,424
1,592
779
1,055
1,785
2,034
OPM %
15%
20%
21%
20%
16%
20%
32%
29%
26%
15%
19%
26%
28%
Other Income
34
4
32
29
15
5
23
14
6
24
75
47
54
Interest
106
111
100
80
88
90
68
102
165
183
216
171
161
Depreciation
62
86
106
125
164
187
205
251
324
385
430
480
487
PBT
67
169
234
237
120
294
1,301
1,084
1,109
236
484
1,182
1,439
Tax %
-2%
21%
19%
29%
22%
13%
24%
23%
28%
29%
27%
25%
—
Net Profit
68
134
190
168
94
255
984
832
793
162
358
890
1,091
EPS in Rs
8.81
16.97
3.6
3.16
1.76
4.77
18.33
15.4
14.67
2.98
6.64
16.46
20.24
Div. Payout %
0%
2%
8%
9%
17%
10%
11%
13%
14%
27%
18%
12%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
16
16
106
106
106
107
107
107
108
108
108
108
Reserves
640
774
1,225
1,377
1,452
1,663
2,490
3,244
3,930
4,003
4,365
5,192
Borrowings
888
1,094
842
980
1,036
1,079
1,482
1,777
2,015
2,577
2,764
2,518
Other Liabilities
345
339
481
554
737
901
1,671
1,840
1,608
1,699
2,099
2,693
Total Liabilities
1,888
2,224
2,653
3,017
3,331
3,750
5,751
6,968
7,660
8,387
9,336
10,511
Fixed Assets
801
1,021
1,230
1,481
1,629
1,726
2,171
2,652
3,409
3,890
4,123
4,371
CWIP
110
70
143
163
110
67
362
813
551
423
458
773
Investments
7
7
3
3
3
3
3
31
50
124
233
309
Other Assets
970
1,126
1,277
1,369
1,589
1,953
3,214
3,472
3,651
3,950
4,521
5,058
Total Assets
1,888
2,224
2,653
3,017
3,331
3,750
5,751
6,968
7,660
8,387
9,336
10,511
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-65
182
332
342
298
347
733
911
994
666
602
1,624
Investing
-397
-312
-289
-384
-253
-221
-941
-914
-997
-822
-680
-1,086
Financing
486
103
-54
42
-45
-128
255
30
-27
250
39
-525
Net Cash Flow
24
-27
-10
1
0
-1
47
27
-30
93
-39
13
Free Cash Flow
-447
-144
55
-49
44
125
49
34
6
-10
61
560
CFO/OP
-24
59
94
98
91
68
62
77
80
99
70
107
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
78
91
109
101
113
102
99
100
96
120
132
115
Inventory Days
210
176
186
201
201
234
266
293
222
277
285
317
Days Payable
102
90
96
107
144
159
199
146
94
158
141
170
Cash Conversion Cycle
186
178
199
195
170
177
166
247
224
240
276
263
Working Capital Days
0
19
3
-11
6
15
43
43
59
42
43
58
ROCE %
14%
16%
16%
14%
8%
14%
40%
26%
23%
7%
9%
18%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Laurus Labs insights

70 extracted metrics + investor summaries across FY06–FY27.

Log in — free

Shareholding Pattern

FIIs28.00%Promot.27.47%Others10.30%DIIs13.74%Public20.49%As ofJun 2026
2.69% of promoter holding pledged as of Jun 2026

Documents

Frequently Asked Questions about Laurus Labs

What does Laurus Labs Ltd do?
Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics. They a...
Where is Laurus Labs Ltd (LAURUSLABS) listed?
Laurus Labs Ltd trades as LAURUSLABS on the NSE and under code 540222 on the BSE.
Which sector does Laurus Labs Ltd belong to?
Laurus Labs Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Laurus Labs Ltd?
Laurus Labs Ltd has a market capitalisation of ₹1,04,478 Cr, which places it in the Large Cap band.
What is the PE ratio of Laurus Labs Ltd?
Laurus Labs Ltd trades at a PE ratio of 97.28, on earnings per share of ₹2.75, against a book value of ₹98.09 per share.
What is the 52-week high and low of Laurus Labs Ltd?
Over the last 52 weeks Laurus Labs Ltd has traded between ₹823.1 and ₹1,955.
Does Laurus Labs Ltd pay dividends?
Laurus Labs Ltd has a dividend yield of 0.10%.
What is the Return on Equity (ROE) of Laurus Labs Ltd?
Laurus Labs Ltd reported a return on equity of 16.38%. Its debt-to-equity ratio is 0.48.

Company Information

Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus employs 6,500+ people, including around 1,050+ scientists, at more than 11 facilities approved by global agencies USFDA, WHO-Geneva, Japan-PDMA, UK-MHRA, EMA, TGA etc. [1]

Website lauruslabs.com
CEO Dr. Satyanarayana Chava M.Sc., Ph.D.
Employees 6,167
Listed 2016-12-19
Face Value ₹ 2
Issued Size 53,98,56,582

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/LAURUSLABS.md for Laurus Labs Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List